7:30 am Check-In & Breakfast
8:25 am Chair’s Opening Remarks
Innovations Within Bispecific Antibodies for Unlocking Success Within Solid Tumors
8:30 am Progressing Co-Stimulatory Bispecific Antibodies for Streamlined Translation into the Clinic & Beyond
Synopsis
- Delving into Regeneron’s advancing co-stimulatory bispecific pipeline
- Combinations of co-stimulatory bispecifics to better mimic natural T cell responses
- Next-gen costimulatory molecules and case studies
9:00 am Zenocutuzumab, a HER2xHER3 Biclonics® Antibody That Can Overcome HER3 Mediated NRG1 Signaling In Tumor Cells By Docking On HER2
Synopsis
- Uncovering Merus’ bispecific antibody screening platform to identify novel Biclonics and Triclonics antibodies
- Detection of NRG1 fusions & therapeutic targeting of NRG1 fusion positive patients, a biomarker-driven rare entity (with a significant unmet medical need)
- Zenocutuzumab shows Robust and Durable Responses in NRG1+ Cancer
9:30 am ImmTACs, a Novel Class of Soluble Bispecifics: What Have We Learned So Far?
Synopsis
- Overview of the technology & challenges associated with the platform
- Clinical proof of concept
- Development of a new ImmTac against PIWIL-1, a novel colorectal cancer target
10:00 am Building Bispecifics using OmniAb’s Next-Generation Therapeutic Antibody and Alternative Scaffold Technologies
Synopsis
- OmniAb’s suite of engineered animals and AI-assisted single B cell discovery workflow offer significant advantages for building bispecifics
- Our naturally optimized fully human custom immune repertoires in multiple host species and multiple modalities provide optionality for our partners and include common light chain platforms in two host species, stabilized human VHH in a chicken host and cow-inspired picobodies. Our AI-augmented single B cell workflows enable deep mining of these vast repertoires to retrieve optimum candidates for drug discovery
- We present a case study using NKp46 as an immunogen in multiple host species and assess the binding kinetics and epitope coverage to inform lead selections for building NK engagers
10:30 am Morning Break
Reinventing Bispecific Drugs for Autoimmune & Inflammatory Diseases
11:30 am Therapeutic Potential of IgM-based Bispecific Antibodies for the Treatment of Refractory Autoimmune Disease Patients
Synopsis
- Highlighting the unique potential of IgM antibodies for treatment of autoimmune disease
- Utilizing T cells to drive deep B cell depletion for B cell mediated autoimmune diseases
- Sharing pipeline updates including the ongoing imvotamab (CD20 x CD3) Phase 1b clinical trials
12:00 pm Reinventing Autoimmune Disease & Cancer Treatment by Harnessing NK Cells
Synopsis
- Validated Flex-NK™ bispecific antibody scaffold for developing next generation of NK cell redirected antibody therapeutics for Autoimmune disease and Cancer
- CD38 a well differentiated target for B cell mediated autoimmune diseases and the unique mechanism of action of CYT-338 NK cell engaged
- Cytovia 2.0 emerging pipeline based on NK cell therapy’s for the treatment of autoimmune and cancer indications
12:30 pm Immuno-STATs: a Novel Class of T Cell Engagers for B Cell Depletion in Autoimmune Diseases
Synopsis
- Immuno-STATs are a new class of TCR-selective engagers for selective modulation of disease-relevant T cells
- CUE-100 series Immuno-STATs have been clinically validated in oncology, and have demonstrated significant increase in efficacy (ORR and mPFS) vs SoC
- Here we describe the CUE-500 series, which can re-direct the protective virus-specific T cells (VSTs) to deplete B cells, hence providing unprecedented selectivity for exploiting the killing potential of VSTs, and positions this class of biologics as an attractive alternative for CAR-T approaches
1:00 pm Dose Optimization Strategies for Bispecific T-cell Engagers in Oncology
Synopsis
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies to maximize the efficacy of a drug aswell as the safety and tolerability.
Mechanistic modeling approaches, such as Quantitative Systems Pharmacology (QSP), support this effort by enabling the selection of a more targeted clinical starting and efficacious dose in oncology.
We will present case studies where we developed QSP models in collaboration with our partners to predict efficacious dose and determine First-in-Human starting dose.
1:30 pm Lunch
2:00 pm Considerations on T vs NK Cell Engagers & Case Studies
Synopsis
- Exploring a next generation of NK cell engagers acting via two activating receptors
- Discussing differences between next generations of NK and T cell engages
Going Beyond The Backbone of T Cell Engagers – A New Generation of Immune Cell Engagers
2:30 pm A Next Generation T Cell Engager Leveraging a Novel Format
3:00 pm Roundtable Discussion: Considerations on T vs NK Cell Engagers & Case Studies
Synopsis
- Exploring a next generation of NK cell engagers acting via two activating receptors
- Discussing differences between next generations of NK and T cell engagers
3:30 pm Unlocking the power of diversity-driven discovery and development to amplify success of bispecific lead generation
Synopsis
- Current challenges in generating bispecific antibody therapeutics – solving the combinatorial matrix puzzle and fast-tracking bispecific generation for early-stage functional assessment.
- Fully customized bispecific antibody generation workflow from discovery, characterization to pre-clinical production to pave the path from concept to clinical lead
- Multiparametric, high throughput in silico-driven molecular optimization to derisk programs as early as possible
4:00 pm Afternoon Break
Going Beyond The Backbone of T Cell Engagers – A New Generation of Immune Cell Engagers
5:00 pm Chair’s Closing Remarks & End of Conference
5:00 pm Moving Beyond Bispecifics with Multivalent T cell Engagers in Solid Tumors
Synopsis
- ModeX’s multispecific antibody platform technology designed for syngergistic targeting and streamlined manufacturing in a single product
- The pathway from design, creation, and characterization to the clinic
- Utilizing information about validated targets and known immune mechanisms to characterize clinical safety and efficacy in patients with advanced solid tumors